DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2016" drug pipelines to their offering.
This report provides comprehensive information on the therapeutic development for Acute Renal Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Renal Failure and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Introduction
- Acute Renal Failure Overview
- Therapeutics Development
- Pipeline Products for Acute Renal Failure - Overview
- Pipeline Products for Acute Renal Failure - Comparative Analysis
- Acute Renal Failure - Therapeutics under Development by Companies
- Acute Renal Failure - Therapeutics under Investigation by Universities/Institutes
- Acute Renal Failure Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Acute Renal Failure - Products under Development by Companies
- Acute Renal Failure - Products under Investigation by Universities/Institutes
- Acute Renal Failure - Companies Involved in Therapeutics Development
- A1M Pharma AB
- Adrenomed AG
- Am-Pharma B.V.
- Angion Biomedica Corp.
- Atox Bio Ltd.
- Cellmid Limited
- Complexa, Inc.
- DiaMedica Inc.
- Digna Biotech, S.L.
- DURECT Corporation
- F. Hoffmann-La Roche Ltd.
- G1 Therapeutics, Inc.
- Kringle Pharma, Inc.
For more information about this drug pipelines visit http://www.researchandmarkets.com/research/ks3gkj/acute_renal
Related Topics: Liver and Kidney Disorders Drugs
